VOL. XCIV, NO. 247
WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES
Stock Profile
Waters Corporation (WAT) Moat Analysis
Waters Corporation
WAT · New York Stock Exchange
Weighted across the company's segments.
On Stock Analysis · affiliate link
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Waters became a four-division life-science tools and diagnostics company after its February 9, 2026 Reverse Morris Trust combination with BD Biosciences and Diagnostic Solutions. Q2 2026 revenue was $1.645B: 40.7% Analytical Sciences, 22.4% Biosciences, 31.7% Advanced Diagnostics and 5.3% Materials Sciences. Analytical Sciences customers face switching and validation costs when replacing Empower software. The acquired Biosciences and Advanced Diagnostics equipment creates repeat demand for compatible reagents. Field headcount, annual service contracts and regulated customers reinforce those mechanisms but are not independently scored. Materials Sciences is explicitly moatless on current public evidence. At May 6, 2026, Waters had 98,185,855 common shares outstanding. Integration execution, transition-service dependencies, $4B of assumed debt, platform replacement and customer multi-sourcing remain material risks.
Primary segment
Waters Analytical Sciences
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
4 segments · 9 tags
Updated 2026-09-05
Segments
Waters Analytical Sciences
Liquid chromatography, mass spectrometry, chemistry consumables, compliant informatics and related laboratory service
Revenue
40.7%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Waters Biosciences
Flow cytometry, cellular analysis and sorting, reagents, informatics and single-cell multiomics tools
Revenue
22.4%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Waters Advanced Diagnostics
Microbiology, molecular and multiplex diagnostics, automation, point-of-care testing and clinical specimen workflows
Revenue
31.7%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Waters Materials Sciences
Thermal analysis, rheometry, microcalorimetry and related materials-characterization service and informatics
Revenue
5.3%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
Company-wide advantages
These claims apply across the company segments listed in each claim.
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Empower and related informatics combine instrument control, methods and regulated data records across LC and LC-MS workflows. Waters estimates that Empower was used for roughly 80% of 2023 novel-drug submissions to major regulators; migration can require method, data-integrity and compliance revalidation, though interoperability with competitors' instruments limits hardware lock-in.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Vendor-neutral informatics, open data formats and standardized method transfer can reduce migration costs.
- Cybersecurity, data-integrity or compliance failures could force customers to change platforms.
- Large laboratories can standardize multi-vendor fleets and negotiate enterprise migrations.
Leading indicators
- Empower subscription and renewal growth
- Share of regulated submissions and QA/QC workflows using Empower
- Customer migrations to waters_connect and cloud offerings
Counterarguments
- Waters software interfaces with other manufacturers' instruments, weakening hardware exclusivity.
- The approximately 80% submission statistic is a company estimate and does not mean regulators mandate Empower.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
The acquired Biosciences and Diagnostic Solutions portfolio pairs instruments with reagents, assays and service in repeat testing workflows. Pre-transaction disclosures identified an estimated 70,000-unit installed base and more than 70% annually recurring revenue, supporting recurring pull-through beyond the first two quarters under Waters ownership.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Competing flow-cytometry, microbiology and molecular platforms can win instrument replacements.
- Open assays, commodity specimen products and multi-sourcing can reduce proprietary pull-through.
- Integration or transition-service failures could disrupt reagent availability and customer support.
Leading indicators
- Reagent and recurring-revenue growth
- Instrument placements and replacement win rates
- Service-plan attachment and customer retention
Counterarguments
- The recurring-revenue and installed-base figures are management estimates disclosed before Waters assumed ownership.
- The current release does not separate reagent pull-through, placements or retention by division.
Waters Analytical Sciences
Liquid chromatography, mass spectrometry, chemistry consumables, compliant informatics and related laboratory service
Q2 2026 division revenue was $669m of $1.645B total. The division is the legacy Waters business excluding its Clinical Business Unit. Source: https://www.sec.gov/Archives/edgar/data/1000697/000119312526331413/d163377dex991.htm
Insufficient segment-specific evidence to assign a moat claim.
Waters Biosciences
Flow cytometry, cellular analysis and sorting, reagents, informatics and single-cell multiomics tools
Q2 2026 division revenue was $368m of $1.645B total, versus $358m in the prior-year comparable period. This was the first full quarter under Waters ownership. Source: https://www.sec.gov/Archives/edgar/data/1000697/000119312526331413/d163377dex991.htm
Insufficient segment-specific evidence to assign a moat claim.
Waters Advanced Diagnostics
Microbiology, molecular and multiplex diagnostics, automation, point-of-care testing and clinical specimen workflows
Q2 2026 division revenue was $521m of $1.645B total: $449m Diagnostic Solutions and $72m from the legacy Waters Clinical Business Unit. Source: https://www.sec.gov/Archives/edgar/data/1000697/000119312526331413/d163377dex991.htm
Insufficient segment-specific evidence to assign a moat claim.
Waters Materials Sciences
Thermal analysis, rheometry, microcalorimetry and related materials-characterization service and informatics
Q2 2026 division revenue was $87m of $1.645B total, versus $82m in Q2 2025. No division operating profit or current switching, installed-base or market-share evidence was disclosed. Source: https://www.sec.gov/Archives/edgar/data/1000697/000119312526331413/d163377dex991.htm
Evidence
sold as integrated instrument systems using common software platforms
The filing connects LC and MS instruments through common software rather than presenting informatics as an unrelated product.
using Empower informatics platform
Waters internal analysis estimated that about 80% of novel drugs submitted to the FDA, EMA and China NMPA in 2023 used Empower.
Many of the Company's customers are in highly regulated industries.
Regulated laboratory workflows increase the practical burden of changing validated methods, software and data processes.
instruments and reagent systems
The acquired business develops and sells paired systems for infectious disease, healthcare-associated infection and cancer detection.
>70% Annually Recurring Revenue
The presentation attributes the recurring mix to the combined Biosciences and Diagnostic Solutions portfolio using 2024 results.
Showing 5 of 6 sources.
Risks & Indicators
Erosion risks
- Vendor-neutral informatics, open data formats and standardized method transfer can reduce migration costs.
- Cybersecurity, data-integrity or compliance failures could force customers to change platforms.
- Large laboratories can standardize multi-vendor fleets and negotiate enterprise migrations.
- Competing flow-cytometry, microbiology and molecular platforms can win instrument replacements.
- Open assays, commodity specimen products and multi-sourcing can reduce proprietary pull-through.
- Integration or transition-service failures could disrupt reagent availability and customer support.
Leading indicators
- Empower subscription and renewal growth
- Share of regulated submissions and QA/QC workflows using Empower
- Customer migrations to waters_connect and cloud offerings
- Instrument and chemistry growth inside Empower accounts
- Reagent and recurring-revenue growth
- Instrument placements and replacement win rates
Research WAT elsewhere
Keep the research going
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 73/100 by <a href="https://www.findmymoat.com/stocks/XNYS:WAT">Find My Moat</a> (as of September 2026)More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.